Tirzepatide Shows Superior Kidney Protection Over Dulaglutide in Type 2 Diabetes
Background
People with Type 2 Diabetes (T2D) are at a significantly higher risk of developing chronic kidney disease (CKD), a progressive condition that can lead to kidney failure and cardiovascular complications. While some diabetes medications have shown kidney benefits, a direct comparison of newer dual-agonist therapies like tirzepatide against established GLP-1 receptor agonists like dulaglutide on kidney outcomes has been less clear. This pre-specified exploratory analysis from the SURPASS-CVOT trial aimed to evaluate the comparative effects of tirzepatide and dulaglutide on major kidney events and the rate of kidney function decline in this vulnerable population.
Study Design
This study conducted pre-specified exploratory analyses from the large-scale, randomized, controlled SURPASS-CVOT trial (NCT04255433), which enrolled 13,494 participants with Type 2 Diabetes and established cardiovascular disease or high cardiovascular risk. Participants were randomized to receive either tirzepatide (a dual GLP-1 and GIP receptor agonist) or dulaglutide (a GLP-1 receptor agonist) at standard clinical doses (e.g., 1.5 mg once weekly for dulaglutide, and 5 mg, 10 mg, or 15 mg once weekly for tirzepatide). The trial, sponsored by Eli Lilly and Company, began in 2020 and is expected to complete in 2025, with this analysis focusing on kidney-related endpoints over the study duration.
Results
The analysis revealed that tirzepatide significantly slowed the annual rate of decline in estimated glomerular filtration rate (eGFR), a key measure of kidney function, compared to dulaglutide. In the overall study population, the annual eGFR decline was lower with tirzepatide by a between-group difference of 0.29 mL/min per 1.73 m² (95% CI 0.17 to 0.41; p<0.0001). This protective effect was even more pronounced in participants with pre-existing high-risk chronic kidney disease, where tirzepatide demonstrated a 0.93 mL/min per 1.73 m² lower annual eGFR decline (95% CI 0.65 to 1.22; p<0.0001) compared to dulaglutide. This indicates a substantial and statistically significant benefit for kidney health. Tirzepatide demonstrated a nearly 3.2-fold greater reduction in annual eGFR decline in high-risk CKD patients compared to the overall population when benchmarked against dulaglutide, highlighting its potent renoprotective effects in those most vulnerable.
Key Findings
- Tirzepatide significantly reduced the annual rate of eGFR decline by 0.29 mL/min per 1.73 m² compared to dulaglutide in the overall Type 2 Diabetes population (p<0.0001).
- In patients with high-risk chronic kidney disease, tirzepatide showed an even greater benefit, reducing annual eGFR decline by 0.93 mL/min per 1.73 m² compared to dulaglutide (p<0.0001).
- These kidney-protective effects of tirzepatide were observed in a large-scale, long-term cardiovascular outcomes trial (SURPASS-CVOT) involving over 13,000 participants.
- The superior renoprotective effect of tirzepatide over dulaglutide suggests a potential new standard for managing Type 2 Diabetes patients with kidney concerns.
Why It Matters
These findings are highly significant as they suggest tirzepatide offers superior kidney protection compared to dulaglagutide, a widely used GLP-1 agonist, in patients with Type 2 Diabetes. Given that chronic kidney disease is a major complication of diabetes, the ability of tirzepatide to significantly slow eGFR decline could have profound long-term benefits for patient health, potentially reducing the incidence of kidney failure and the need for dialysis. This evidence strongly supports the potential for tirzepatide to become a preferred therapeutic option for managing Type 2 Diabetes, especially in patients at risk for or with established kidney complications. Future dedicated renal outcomes trials would further solidify these findings and explore additional kidney-specific endpoints.